Meeting
2020 Genitourinary Cancers Symposium
Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.
Authors
Pai-Chi Teng
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
Pai-Chi Teng , Yu Jen Jan , Jie-Fu Chen , Minhyung Kim , Nu Yao , Isla Garraway , Gina Chia-Yi Chu , Pin-Jung Chen , Jasmine Jiemei Wang , Yi-Te Lee , Yazhen Zhu , Leland WK Chung , Felix Y Feng , Michael Freeman , Sungyong You , Hsian-Rong Tseng , Edwin M. Posadas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 170)
Abstract #
170
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices.
First Author: Gordon Andrew Brown
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
First Author: Michael Philip Sun